Fortis Capital Advisors’s Amedisys AMED Stock Holding History

Fortis Capital Advisors’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-44	Closed	-$3.24K	–	131
2023 Q1	$3.24K	Buy	+44	New	+$3.81K	﹤0.01%	537

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Fortis Capital Advisors's AMED Position: Q2 2023 in Review

Fortis Capital Advisors sold out of Amedisys (AMED) in Q2 2023, closing a stake of 44 shares — an estimated $3.24K sold.

Fortis Capital Advisors first reported a position in AMED in Q1 2023 and held it in 1 quarter. The position peaked at $3.24K in Q1 2023. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

Fortis Capital Advisors reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
Fortis Capital Advisors sold 44 Amedisys shares in Q2 2023, an estimated $3.24K.
Fortis Capital Advisors first reported a position in Amedisys in Q1 2023 and held it in 1 quarter.
Fortis Capital Advisors's Amedisys position peaked at $3.24K in Q1 2023.
301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Fortis Capital Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.